Dermatologists must be aware of the adverse effects of antimicrobial agents as well as various drug interactions that may influence the choice of drug as well as specific drug schedules. The development of modern antibacterials has improved the treatment of cutaneous @entity2348 . @entity7646 antibacterials continue to be an important therapeutic class of drugs with established efficacy in a variety of @entity272 . All macrolides inhibit protein synthesis by reversibly binding to the 23S ribosomal RNA in the 50S-subunit. @entity2929 , the prototype of @entity7646 antibacterials, was isolated from the metabolic products of a strain of Streptomyces erytherus in 1952. Originally, @entity2929 was introduced as an alternative to @entity114 because of its activity against the Gram-positive organisms. Numerous studies have demonstrated the efficacy and safety of @entity2929 for various @entity166 . Unfortunately, @entity2929 is associated with a number of drawbacks including a narrow spectrum of activity, unfavorable pharmacokinetic properties, poor gastrointestinal tolerability, and a significant number of drug-drug interactions. Newer macrolides have been developed to address these limitations. The pharmacokinetics of @entity4580 and @entity4581 allow for shorter dosing schedules because of prolonged tissue levels. The efficacy of @entity4580 for the treatment of skin and soft tissue infections in adults and @entity1 is well established. The unique pharmakinetics of @entity4580 makes it a suitable agent for the treatment of acne. @entity4581 represents a clear advance in the @entity7646 management of @entity1 with @entity1201 and @entity272 with atypical mycobacteria. @entity9848 and @entity14698 display no clinical or bacteriological adcantage over @entity2929 despite a superior pharmacokinetic profile. An area of concern is the increasing @entity7646 resistance that is being reported with some of the common pathogens which may limit the clinical usefulness of this class of antimicrobial agents in future.

A guide to selection and appropriate use of macrolides in XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity9848 :: ('MESH:C053853', 'Chemical') :: ['Dirithromycin'] @entity7646 :: ('CHEBI:25106', 'Chemical') :: ['macrolide', 'Macrolide'] @entity114 :: ('MESH:D010406', 'Chemical') :: ['penicillin'] @entity4581 :: ('MESH:D017291', 'Chemical') :: ['Clarithromycin', 'clarithromycin'] @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin', 'Erythromycin'] @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections'] @entity4580 :: ('MESH:D017963', 'Chemical') :: ['azithromycin'] @entity14698 :: ('MESH:D015575', 'Chemical') :: ['roxithromycin'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin infections'] @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases'] @entity1201 :: ('MESH:D007918', 'Disease') :: ['leprosy']
@entity272 :: (MESH:D012871,Disease) :: ['skin infections']
